At the news
? BEARISHIMPACT 6/10 8-K filed Aug 14, 2026 at 16:09 ET
Zentalis Pharmaceuticals priced a public offering of 23,000,000 shares of common stock at $3.50 per share, with an underwriter option for an additional 3,450,000 shares. The company expects net proceeds of approximately $75.1 million to fund clinical trials, manufacturing, and general corporate purposes. This dilutive offering represents a significant portion of the company's pre-offering market cap of $297M.
- 23,000,000 shares of common stock offered at $3.50 per share
- Underwriters have a 30-day option to purchase up to an additional 3,450,000 shares
- Estimated net proceeds of approximately $75.1 million
- Closing expected August 17, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access